Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
|
| Abstract |
A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. Eighteen patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy, received oxaliplatin 130 mg/m2 i.v. every 21 days. Patients were treated until tumor progression or unacceptable toxicity. No objective response was observed among the 18 treated patients. Three (16.7%) patients had stable disease for > 2 months. A clinical benefit response was observed in five (27.7%) patients. Toxicity was mild. Oxaliplatin as second-line treatment for patients with unresectable pancreatic cancer is well tolerated and associated with improvement of tumor-related symptoms despite its failure to induce objective responses. LOHP merits further investigation in combination with other drugs as palliative treatment of pretreated patients with advanced pancreatic cancer.
|
|---|---|
| Authors | Nikolaos Androulakis, Konstantinos Syrigos, Aristidis Polyzos, Gerasimos Aravantinos, George P Stathopoulos, Nikolaos Ziras, Konstantinos Mallas, Lambros Vamvakas, Vassilis Georgoulis, Hellenic Oncology Research Group |
| Journal | Cancer investigation (Cancer Invest) Vol. 23 Issue 1 Pg. 9-12 ( 2005) ISSN: 0735-7907 [Print] England |
| PMID | 15779862 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!